This timely book reviews the current status of drug treatments in dementia, both in practice and in research. It commences with a brief overview of the dementia syndrome and provides guidance in making a diagnosis. It then focuses on treatment of the cognitive function, psychological and behavioural symptoms and co-existing diseases. Chapters devoted to measuring the effects and cost-effectiveness of anti-dementia drugs are included.

"Reducing the use of psychotropic drugs in the symptomatic treatment of dementia is key to successfully implementing compassionate, person-centered practices in your organization - and this book shows clearly why and how it can be done. The revised second edition of this award-winning resource introduces new research, language, and examples to reinforce the core message that antipsychotic medications are not the solution to ease the distress experienced by individuals living with dementia. Outlined here is the information and inspiration you need to provide alternative solutions for individualized support and care"--Cover.

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.

Frontiers in Clinical Drug Research - Dementia is a book series which presents comprehensive reviews about research on Dementia, - the loss of brain function associated with Alzheimer’s disease and other related medical conditions. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for dementia and related disorders. This volume includes the following reviews: - Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer’s Disease - Cholesterol in Brain Health and Pathologies - Advances in the Treatment of Mild Cognitive Impairment (MCI) and Dementia - Analytical Methods in Alzheimer’s Disease Drug Discovery - Targeting Alzheimer’s Disease through Nanomedicine - Current Challenges in Alzheimer’s Disease Research - Metals Linked to Alzheimer's Disease

This practice and training guide is written with the needs of health and social care professionals working with people with dementia in mind. The book is illustrated with case studies and includes a chapter on understanding and responding to the needs of the carer - such as access to information and support - and the effect on their own health.

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions - Tau-targeted therapy in Alzheimer's disease - history and current state - Emerging nanotherapeutic strategies in Alzheimer's disease - Implication of dehydroepiandrosterone on dementia related to oxidative stress - Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Filling a noticeable gap in the market for a new text solely focused on Dementia with Lewy Bodies, this book discusses cutting-edge topics covering the condition from diagnosis to management, as well as what is known about the neurobiological changes involved. With huge progress having been made over the last decade in terms of the disorder